Clinical trials: Thromboembolic Disorders
Mechanical Heart Valve Recipients
Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications
We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
- Trial name
- ESCAT III (NCT00528671)
- Testing
- phenprocoumon
- Where
- Germany
- Volunteers
- 1,571 people
- Sponsor
- Heart and Diabetes Center North-Rhine Westfalia
Covid19, Thrombosis
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.
- Trial name
- APOLLO (NCT04746339)
- Testing
- Apixaban 2.5 MG
- Where
- 4 sites in Brazil
- Volunteers
- 411 people
- Sponsor
- Brazilian Clinical Research Institute
Antithrombin III Deficiency
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.
- Trial name
- NCT00319228
- Testing
- Plasma-derived AT-III concentrate
- Volunteers
- 3 people
- Sponsor
- Instituto Grifols, S.A.
Atrial Fibrillation, Tachycardia
Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems
This is an observational registry study aiming to collect data on efficacy and safety of the single chamber Biotronik DX system with enhanced atrial diagnostics. The minimal follow-up period is 24 months.
- Conditions
- Atrial Fibrillation, Tachycardia, ICD Therapy, Thromboembolic Events
- Trial name
- MATRIX (NCT01774357)
- Where
- Germany
- Volunteers
- 2,054 people
- Sponsor
- Biotronik SE & Co. KG
Severe Aortic Valve Stenosis
Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation
The POPular ATLANTIS trial aims to investigate CT-guided antithrombotic therapy compared to lifelong single antiplatelet therapy after a transcatheter aortic valve implantation (TAVI) procedure.
- Trial name
- POP ATLANTIS (NCT06168370)
- Testing
- CT guided strategy
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- St. Antonius Hospital
Thromboembolism, Hemolysis
Lavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device
Left ventricular assist device (LVAD) patients remain at risk for pump thrombus and thromboembolic events through multiple mechanisms.
- Conditions
- Thromboembolism, Hemolysis, Stroke
- Trial name
- NCT04199793
- Testing
- Lavare On, Lavare Off
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt University Medical Center
Aortic Valve Stenosis
Protamine Sulfate During Transcatheter Aortic Valve Implantation
Transcatheter aortic valve implantation (TAVI) is a new, rapidly emerging standard of care in inoperable and high-risk patients with severe, symptomatic aortic stenosis.
- Trial name
- PS TAVI (NCT02974660)
- Testing
- Protamine sulfate, 0.9% NaCl
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty
This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).
- Trial name
- NCT03409588
- Testing
- Adempas
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension
Assessment of the prognostic value of the estimation of plasma volume or its variation in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) after acute right heart…
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Acute Right Heart Failure
- Trial name
- NCT05861479
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
COVID 19, Thromboembolic and Bleeding Complications
Thromboembolic Complications in Mild Covid-19 Cases
The aim of the study is to investigate the frequency of thromboembolic complications and the factors influencing them in COVID-19 cases that did not require hospitalization.
- Conditions
- COVID 19, Thromboembolic and Bleeding Complications, Thromboembolism, Venous, Post COVID-19
- Trial name
- NCT06695377
- Where
- Turkey (Türkiye)
- Volunteers
- 961 people, healthy volunteers welcome
- Sponsor
- Marmara University Pendik Training and Research Hospital
Venous Thromboembolic Disease
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
Elderly subjects are at greater risk of thrombophlebitis than the general population, but also of bleeding when anticoagulant therapy is initiated.
- Trial name
- ENOX-VTD-H (NCT05150314)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Strasbourg, France
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Thromboembolism
A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).
This is a multicentre, randomized, double-blind, placebo controlled study. During this study all the patients will receive background venous thromboembolism (VTE) mechanical prophylaxis with intermittent pneumatic compression…
- Trial name
- NCT00038961
- Testing
- fondaparinux sodium
- Volunteers
- 1,309 people
- Sponsor
- GlaxoSmithKline
Thrombosis Embolism, Thromboses, Venous
Cancer-related Venous Thromboembolic Disease - Cohort Study
Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)).
- Conditions
- Thrombosis Embolism, Thromboses, Venous, Cancer
- Trial name
- CAPE (NCT06393764)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Congenital Heart Defects, Atrial Fibrillation
NOACs for Atrial Tachyarrhythmias in Congenital Heart Disease
Rationale: Adult patients with congenital heart disease (CHD) with atrial tachyarrhythmias need to be anticoagulated. It is not known whether non-vitamin K antagonist oral anticoagulants (NOAC) in this patient group are efficient…
- Conditions
- Congenital Heart Defects, Atrial Fibrillation, Ectopic Atrial Tachycardia
- Trial name
- NOTE (NCT02928133)
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Spinal Cord Injury
Prospective and Monocentric Study of the Incidence of Venous Thromboembolic Disease (VTE) in Spinal Cord Injury (SCI) Patient Between 3 and 12 Months After SCI
Venous Thromboembolic Disease (VTE) in SCI patients is very common, its prevalence is 60 to 80% against 10-20% in the general population.
- Trial name
- IMATEM (NCT02796235)
- Testing
- Venous Doppler ultrasound of the lower limbs
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Nantes University Hospital
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03195010
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases
Thromboembolic Disease
Safety of Direct Oral Anticoagulant During Pregnancy
Pregnancy is a major risk factor of thromboembolic disease (2 to 10 increased risk of thromboembolic event for pregnant women). This risk is related to the physiological changes inducing venous stasis and hypercoagulability.
- Trial name
- SACOD (NCT06179823)
- Where
- France
- Volunteers
- 1,755,558 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France